C
Canid
Service to manage the complexity of vaccine operations for medical practices, so that the practices can focus on providing care to their patients
About Canid
Canid.io is a specialized startup focused on streamlining vaccine operations for pediatricians, primarily in New York State. The company addresses a critical need in the healthcare sector by managing the entire vaccine process, from inventory management and purchasing to registry uploads and billing health plans. This allows pediatricians to concentrate on their primary responsibility—taking care of children—without the administrative burden and financial strain associated with vaccine procurement and insurance reimbursements.
Canid.io serves pediatricians and pediatric clinics, ensuring they have timely access to vaccines and receive fair compensation for their services. The company operates in the healthcare market, specifically targeting pediatric healthcare providers. By handling the complexities of vaccine logistics and billing, Canid.io enables these healthcare professionals to deliver vaccinations more efficiently and effectively.
The business model of Canid.io is service-based, where the company offers its comprehensive vaccine management services at no upfront cost to the pediatricians. Instead, Canid.io makes money by taking a percentage of the reimbursements from insurance plans, ensuring that pediatricians are paid fairly for their work without having to navigate the intricate insurance landscape themselves.
In summary, Canid.io is a vital partner for pediatricians, simplifying vaccine operations and ensuring that children receive timely vaccinations. By taking on the logistical and financial challenges of vaccine management, Canid.io allows pediatricians to focus on their core mission of child healthcare.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2020
- Headquarters
- New York City, United States
- Employees
- 78
- Open positions
- None listed
- Dealroom signal
- 83.7/100
- Industry
- Health
- Sub-industry
- Health Platform
- Sector
- Health Tech & Medtech, Hard Tech
- Business model
- Marketplace & ecommerce
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Jun 2025 | $10M | $40M | SeedToB Capital · Brooklyn Bridge Ventures · FJ Labs · Telescope Partners | ↗ |
| SEEDOther financing | Sep 2023 | $1.5M | $6M | FJ Labs · I2BF Global Ventures · Alumni Ventures · MKT1 | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Canid is 3K monthly website visits, down 23.1% over the last three months. Canid's team grew 6.8% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed6 investors entered at this stage
Brooklyn Bridge Ventures
FJ Labs
SeedToB Capital
I2BF Global Ventures
Alumni Ventures
MKT1
Series A1 investor entered at this stage
Telescope Partners
Other known investors3 additional known investors
Edward Lando
Jon Oringer
Nadav Ben-Chanoch
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Canid on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Canid’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







